GGrantIndex
← Leaderboards

Edith A Perez

Mayo Clinic Coll Of Medicine, Rochester

$1,891,637
Attributed
$4,161,076
Total exposure
3
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.6M · FY200815
$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15

Funding mix

By agency

NIH$16,056,090 · 4

By mechanism

U10$12,052,754 · 2
R01$4,003,336 · 2

Most similar at Mayo Clinic Coll Of Medicine, Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Multidisciplinary

Research focus

MultidisciplinaryTumorResponseBaseClinical TrialsNorth Central Cancer Treatment GroupMalignant Breast NeoplasmCancer PatientInsightMalignant NeoplasmsCancer TherapyPathogenesisPatient CareMolecularDesignGenotypeEnrollmentBreastGeneticClinicClinical CareBiological MarkersAdjuvantHumanized Monoclonal Antibodies

Grant awards (18)

Alliance for Clinical Trials in Oncology Operations Center$810,357
U10 · FY2015 · CA
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$534,720
R01 · FY2015 · CA · contact PI
Alliance for Clinical Trials in Oncology Operations Center$34,176
U10 · FY2015 · CA
Alliance for Clinical Trials in Oncology Operations Center$10,540,919
U10 · FY2014 · CA
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$521,566
R01 · FY2014 · CA · contact PI
Alliance for Clinical Trials in Oncology Operations Center$264,661
U10 · FY2014 · CA
Alliance for Clinical Trials in Oncology Operations Center$228,063
U10 · FY2014 · CA
Alliance for Clinical Trials in Oncology Operations Center$16,838
U10 · FY2014 · CA
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$511,906
R01 · FY2013 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$549,804
R01 · FY2012 · CA · contact PI
Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab$619,306
R01 · FY2011 · CA · contact PI
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$198,652
R01 · FY2011 · CA · contact PI
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$198,218
R01 · FY2010 · CA · contact PI
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$483,070
R01 · FY2009 · CA · contact PI
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$386,094
R01 · FY2008 · CA · contact PI
BREAST CANCER$78,870
U10 · FY2002 · CA
BREAST CANCER$78,870
U10 · FY2002 · CA
BREAST CANCER$0
U10 · FY2001 · CA